Trial Review

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT02145468




Registration number
NCT02145468
Ethics application status
Date submitted
15/05/2014
Date registered
23/05/2014
Date last updated
2/06/2017

Titles & IDs
Public title
A Phase 3 Clinical Outcomes Study to Compare the Incidence of Major Adverse Cardiovascular Events in Subjects Presenting With Acute Coronary Syndrome Treated With Losmapimod Compared to Placebo (LATITUDE-TIMI 60)
Scientific title
A Clinical Outcomes Study to Compare the Incidence of Major Adverse Cardiovascular Events in Subjects Presenting With Acute Coronary Syndrome Treated With Losmapimod Compared to Placebo (PM1116197) LosmApimod To Inhibit p38 MAP Kinase as a TherapeUtic Target and moDify Outcomes After an Acute Coronary syndromE (LATITUDE)-TIMI 60.
Secondary ID [1] 0 0
116197
Universal Trial Number (UTN)
Trial acronym
LATITUDE
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Acute Coronary Syndrome 0 0
Condition category
Condition code
Cardiovascular 0 0 0 0
Coronary heart disease
Other 0 0 0 0
Research that is not of generic health relevance and not applicable to specific health categories listed above

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Losmapimod 7.5 mg twice daily
Treatment: Drugs - Placebo twice daily
Treatment: Drugs - Standard therapy

Experimental: Losmapimod - Losmapimod 7.5 mg twice daily oral tablet

Placebo comparator: Placebo - Placebo twice daily oral tablet


Treatment: Drugs: Losmapimod 7.5 mg twice daily
Subjects will receive Losmapimod 7.5 mg as film-coated, round, plain faced tablets.

Treatment: Drugs: Placebo twice daily
Subjects will receive placebo as film-coated, round, plain faced tablets.

Treatment: Drugs: Standard therapy
Subjects will receive standard therapy consistent with the appropriate guidelines from professional societies. The standard therapy includes nitrates, morphine sulfate, beta adrenergic blockers, renin-angiotensin aldosterone inhibitors, other anti-ischemic therapies, and analgesic therapy.
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Number of Participants With First Occurrence of Major Adverse Cardiovascular Events (MACE) Through Week 12
Timepoint [1] 0 0
Up to 12 weeks
Secondary outcome [1] 0 0
Number of Participants With First Occurrence of MACE Through Week 24
Timepoint [1] 0 0
Up to Week 24
Secondary outcome [2] 0 0
Number of Participants With First Occurrence of the Composite of CV Death or MI up to Week 12 and Week 24
Timepoint [2] 0 0
Week 12 and Week 24
Secondary outcome [3] 0 0
Number of Participants With First Occurrence of the Composite of CV Death, MI or Hospitalization for Heart Failure (HF) up to Week 12 and Week 24.
Timepoint [3] 0 0
Week 12 and Week 24
Secondary outcome [4] 0 0
Number of Participants With First Occurrence of the Expanded Composite of Arterial CV Events Defined as CV Death, MI, SRI-UR or Stroke Through to Week 12 and Week 24
Timepoint [4] 0 0
Week 12, Week 24
Secondary outcome [5] 0 0
Number of Participants With First Occurrence of the Composite of Coronary Events Defined as CHD Death, MI, SRI-UR or Any Unplanned Coronary Artery Revascularization Through to Week 12 and Week 24
Timepoint [5] 0 0
Week 12, Week 24
Secondary outcome [6] 0 0
Number of Participants With First Occurrence of the Composite of CV Death or Hospitalization for HF Through to Week 12 and Week 24
Timepoint [6] 0 0
Week 12, Week 24
Secondary outcome [7] 0 0
Number of Participants With First Occurrence of the Composite of CV Death, MI or Stroke Through to Week 12 and Week 24
Timepoint [7] 0 0
Week 12, Week 24
Secondary outcome [8] 0 0
Number of Participants With First Occurrence of the Expanded Composite of CV Death, MI, SRI-UR, Stroke or Hospitalization for HF Through to Week 12 and Week 24
Timepoint [8] 0 0
Week 12, Week 24
Secondary outcome [9] 0 0
Number of Participants With First Occurrence of the Composite of CHD Death, MI or SRI-UR Through to Week 12 and Week 24
Timepoint [9] 0 0
Week 12, Week 24
Secondary outcome [10] 0 0
Number of Participants With First Occurrence of the Composite of CHD Death or MI Through to Week 12 and Week 24
Timepoint [10] 0 0
Week 12, Week 24
Secondary outcome [11] 0 0
Number of Participants With First Occurrence of the Composite of All-cause Death, MI or SRI-UR Through to Week 12 and Week 24
Timepoint [11] 0 0
Week 12, Week 24
Secondary outcome [12] 0 0
Number of Participants With First Occurrence of the Composite of All-cause Death or MI Through to Week 12 and Week 24
Timepoint [12] 0 0
Week 12, Week 24
Secondary outcome [13] 0 0
Number of Participants With First Occurrence of the Composite of CV Death, Type I (Spontaneous) MI or SRI-UR Through to Week 12 and Week 24
Timepoint [13] 0 0
Week 12, Week 24
Secondary outcome [14] 0 0
Number of Participants With First Occurrence of the Composite of CV Death or Type I (Spontaneous) MI Through to Week 12 and Week 24
Timepoint [14] 0 0
Week 12, Week 24
Secondary outcome [15] 0 0
Number of Participants With First Occurrence of Definite or Probable Stent Thrombosis Through to Week 12 and Week 24
Timepoint [15] 0 0
Week 12, Week 24
Secondary outcome [16] 0 0
Number of Participants Re-hospitalized Within 30 Days of Discharge
Timepoint [16] 0 0
Within up to 30 days of post discharge
Secondary outcome [17] 0 0
Number of Participants With All-cause Mortality Through to Week 12 and Week 24
Timepoint [17] 0 0
Week 12, Week 24
Secondary outcome [18] 0 0
Number of Participants With CV Death Events Through to Week 12 and Week 24
Timepoint [18] 0 0
Week 12, Week 24
Secondary outcome [19] 0 0
Number of Participants With CHD Death Events Through to Week 12 and Week 24
Timepoint [19] 0 0
Week 12, Week 24
Secondary outcome [20] 0 0
Number of Participants With First Occurrence of Myocardial Infarction (Fatal and Non-fatal) Events Through to Week 12 and Week 24
Timepoint [20] 0 0
Week 12, Week 24
Secondary outcome [21] 0 0
Number of Participants With First Occurrence of Type I (Spontaneous) MI Events Through to Week 12 and Week 24
Timepoint [21] 0 0
Week 12, Week 24
Secondary outcome [22] 0 0
Number of Participants With First Occurrence of SRI-UR Events Through to Week 12 and Week 24
Timepoint [22] 0 0
Week 12, Week 24
Secondary outcome [23] 0 0
Number of Participants With First Occurrence of Stroke (Fatal and Non-fatal) Events Through to Week 12 and Week 24
Timepoint [23] 0 0
Week 12, Week 24
Secondary outcome [24] 0 0
Number of Participants With First Occurrence of Hospitalization for HF Through to Week 12 and Week 24
Timepoint [24] 0 0
Week 12, Week 24
Secondary outcome [25] 0 0
Number of Participants With First Occurrence of Any Unplanned Coronary Revascularization Through to Week 12 and Week 24
Timepoint [25] 0 0
Week 12, Week 24

Eligibility
Key inclusion criteria
* Signed written informed consent
* Men or women at least 35 years old. Women must be post-menopausal or using a highly effective method for avoidance of pregnancy
* Hospitalization for NSTEMI or STEMI (Universal Definition Type 1 MI)
* With the following timing of symptoms: NSTEMI: Presence of ischemic symptoms (>=5 minutes) at rest within 24 hours prior to randomization (may include qualifying episode). STEMI: Onset of qualifying ischemic symptoms within 12 hours of randomization.
* At least one of the following
* Age >=60 years at randomization.
* Myocardial infarction prior to the qualifying ACS event
* CABG prior to qualifying ACS event.
* NSTEMI with new ischemic ST-segment depression >= 0.1 mV in >= 2 contiguous leads.
* Diabetes mellitus requiring pharmacotherapy.
* Coexistent clinically diagnosed arterial disease
Minimum age
35 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Unable to be randomized prior to coronary revascularization or fibrinolysis for the qualifying MI.
* Current severe heart failure or shock
* Ongoing clinical instability
* History of chronic liver disease
* Known severe renal impairment
* Any condition, other than vascular disease, with life expectancy <1 year that might prevent the subject from completing the study.
* Known active tuberculosis, HIV, active opportunistic or life threatening infections.
* Vaccination with a live attenuated vaccine within 6 weeks of randomization.
* Concomitant use of cytotoxic chemotherapy for cancer or known ongoing or anticipated use of chronic severe immunosuppressive agents
* Positive pregnancy test or is known to be pregnant or lactating
* Known alcohol or drug abuse within the past 6 months
* Any current mental condition, which may affect study compliance or prevent understanding of the aims, investigational procedures or possible consequences of the study.
* Participation in a study of an investigational medication within the past 30 days.
* Anticipated inability to comply with any study procedures, including participation in study visits according to the visit schedule through 24 weeks.
* Use of another investigational product within 30 days or 5 half-lives (whichever is longer) or according to local regulations, or currently participating in a study of an investigational device. Subjects must be randomized only one time in this investigational study
* Any other reason the investigator deems the subject to be unsuitable for the study

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s

Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
3/06/2014
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
14/12/2015
Sample size
Target
Accrual to date
Final
3503
Recruitment in Australia
Recruitment state(s)
QLD,SA,TAS,VIC,WA
Recruitment hospital [1] 0 0
GSK Investigational Site - Brisbane
Recruitment hospital [2] 0 0
GSK Investigational Site - Cairns
Recruitment hospital [3] 0 0
GSK Investigational Site - Herston
Recruitment hospital [4] 0 0
GSK Investigational Site - Nambour
Recruitment hospital [5] 0 0
GSK Investigational Site - Bedford Park
Recruitment hospital [6] 0 0
GSK Investigational Site - Hobart
Recruitment hospital [7] 0 0
GSK Investigational Site - Epping
Recruitment hospital [8] 0 0
GSK Investigational Site - Geelong
Recruitment hospital [9] 0 0
GSK Investigational Site - Murdoch
Recruitment hospital [10] 0 0
GSK Investigational Site - Nedlands
Recruitment postcode(s) [1] 0 0
4032 - Brisbane
Recruitment postcode(s) [2] 0 0
4870 - Cairns
Recruitment postcode(s) [3] 0 0
4029 - Herston
Recruitment postcode(s) [4] 0 0
4560 - Nambour
Recruitment postcode(s) [5] 0 0
5042 - Bedford Park
Recruitment postcode(s) [6] 0 0
7000 - Hobart
Recruitment postcode(s) [7] 0 0
3076 - Epping
Recruitment postcode(s) [8] 0 0
3220 - Geelong
Recruitment postcode(s) [9] 0 0
6150 - Murdoch
Recruitment postcode(s) [10] 0 0
6009 - Nedlands
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
Arizona
Country [3] 0 0
United States of America
State/province [3] 0 0
Arkansas
Country [4] 0 0
United States of America
State/province [4] 0 0
California
Country [5] 0 0
United States of America
State/province [5] 0 0
Colorado
Country [6] 0 0
United States of America
State/province [6] 0 0
Florida
Country [7] 0 0
United States of America
State/province [7] 0 0
Georgia
Country [8] 0 0
United States of America
State/province [8] 0 0
Idaho
Country [9] 0 0
United States of America
State/province [9] 0 0
Illinois
Country [10] 0 0
United States of America
State/province [10] 0 0
Indiana
Country [11] 0 0
United States of America
State/province [11] 0 0
Iowa
Country [12] 0 0
United States of America
State/province [12] 0 0
Louisiana
Country [13] 0 0
United States of America
State/province [13] 0 0
Maine
Country [14] 0 0
United States of America
State/province [14] 0 0
Massachusetts
Country [15] 0 0
United States of America
State/province [15] 0 0
Michigan
Country [16] 0 0
United States of America
State/province [16] 0 0
Minnesota
Country [17] 0 0
United States of America
State/province [17] 0 0
Missouri
Country [18] 0 0
United States of America
State/province [18] 0 0
Nebraska
Country [19] 0 0
United States of America
State/province [19] 0 0
New Jersey
Country [20] 0 0
United States of America
State/province [20] 0 0
New York
Country [21] 0 0
United States of America
State/province [21] 0 0
North Carolina
Country [22] 0 0
United States of America
State/province [22] 0 0
Ohio
Country [23] 0 0
United States of America
State/province [23] 0 0
Oklahoma
Country [24] 0 0
United States of America
State/province [24] 0 0
Pennsylvania
Country [25] 0 0
United States of America
State/province [25] 0 0
South Carolina
Country [26] 0 0
United States of America
State/province [26] 0 0
South Dakota
Country [27] 0 0
United States of America
State/province [27] 0 0
Tennessee
Country [28] 0 0
United States of America
State/province [28] 0 0
Texas
Country [29] 0 0
United States of America
State/province [29] 0 0
Virginia
Country [30] 0 0
United States of America
State/province [30] 0 0
Washington
Country [31] 0 0
United States of America
State/province [31] 0 0
West Virginia
Country [32] 0 0
United States of America
State/province [32] 0 0
Wisconsin
Country [33] 0 0
Argentina
State/province [33] 0 0
Buenos Aires
Country [34] 0 0
Argentina
State/province [34] 0 0
Santa Fe
Country [35] 0 0
Argentina
State/province [35] 0 0
Ciudad Autonoma de Buenos Aires
Country [36] 0 0
Argentina
State/province [36] 0 0
Corrientes
Country [37] 0 0
Belgium
State/province [37] 0 0
Aalst
Country [38] 0 0
Belgium
State/province [38] 0 0
Bonheiden
Country [39] 0 0
Belgium
State/province [39] 0 0
Brasschaat
Country [40] 0 0
Belgium
State/province [40] 0 0
Brugge
Country [41] 0 0
Belgium
State/province [41] 0 0
Genk
Country [42] 0 0
Belgium
State/province [42] 0 0
Gent
Country [43] 0 0
Belgium
State/province [43] 0 0
Leuven
Country [44] 0 0
Belgium
State/province [44] 0 0
Liège
Country [45] 0 0
Belgium
State/province [45] 0 0
Mechelen
Country [46] 0 0
Belgium
State/province [46] 0 0
Yvoir
Country [47] 0 0
Bulgaria
State/province [47] 0 0
Blagoevgrad
Country [48] 0 0
Bulgaria
State/province [48] 0 0
Dimitrovgrad
Country [49] 0 0
Bulgaria
State/province [49] 0 0
Pazardjik
Country [50] 0 0
Bulgaria
State/province [50] 0 0
Sofia
Country [51] 0 0
Canada
State/province [51] 0 0
British Columbia
Country [52] 0 0
Canada
State/province [52] 0 0
Ontario
Country [53] 0 0
Canada
State/province [53] 0 0
Quebec
Country [54] 0 0
Chile
State/province [54] 0 0
Región De La Araucania
Country [55] 0 0
Chile
State/province [55] 0 0
Región Del Biobio
Country [56] 0 0
Chile
State/province [56] 0 0
Región Metro De Santiago
Country [57] 0 0
Chile
State/province [57] 0 0
Santiago
Country [58] 0 0
Czechia
State/province [58] 0 0
Brno
Country [59] 0 0
Czechia
State/province [59] 0 0
Ceske Budejovice
Country [60] 0 0
Czechia
State/province [60] 0 0
Hradec Kralove
Country [61] 0 0
Czechia
State/province [61] 0 0
Liberec
Country [62] 0 0
Czechia
State/province [62] 0 0
Ostrava.
Country [63] 0 0
Czechia
State/province [63] 0 0
Pardubice
Country [64] 0 0
Czechia
State/province [64] 0 0
Praha 10
Country [65] 0 0
Czechia
State/province [65] 0 0
Praha 2
Country [66] 0 0
Czechia
State/province [66] 0 0
Praha 6
Country [67] 0 0
Czechia
State/province [67] 0 0
Usti nad Labem
Country [68] 0 0
Czechia
State/province [68] 0 0
Zlin
Country [69] 0 0
Denmark
State/province [69] 0 0
Hellerup
Country [70] 0 0
Denmark
State/province [70] 0 0
Hvidovre
Country [71] 0 0
Denmark
State/province [71] 0 0
København NV
Country [72] 0 0
Denmark
State/province [72] 0 0
København S
Country [73] 0 0
Estonia
State/province [73] 0 0
Tallinn
Country [74] 0 0
Estonia
State/province [74] 0 0
Tartu
Country [75] 0 0
France
State/province [75] 0 0
Besançon Cedex
Country [76] 0 0
France
State/province [76] 0 0
Dijon
Country [77] 0 0
France
State/province [77] 0 0
Montauban cedex
Country [78] 0 0
France
State/province [78] 0 0
Nantes cedex 1
Country [79] 0 0
France
State/province [79] 0 0
Paris Cedex 18
Country [80] 0 0
France
State/province [80] 0 0
Pau
Country [81] 0 0
France
State/province [81] 0 0
Strasbourg cedex
Country [82] 0 0
France
State/province [82] 0 0
Toulouse cedex 09
Country [83] 0 0
France
State/province [83] 0 0
Tourcoing cedex
Country [84] 0 0
France
State/province [84] 0 0
Valenciennes Cedex
Country [85] 0 0
Germany
State/province [85] 0 0
Baden-Wuerttemberg
Country [86] 0 0
Germany
State/province [86] 0 0
Brandenburg
Country [87] 0 0
Germany
State/province [87] 0 0
Hessen
Country [88] 0 0
Germany
State/province [88] 0 0
Niedersachsen
Country [89] 0 0
Germany
State/province [89] 0 0
Nordrhein-Westfalen
Country [90] 0 0
Germany
State/province [90] 0 0
Sachsen
Country [91] 0 0
Germany
State/province [91] 0 0
Hamburg
Country [92] 0 0
Greece
State/province [92] 0 0
Alexandroupolis
Country [93] 0 0
Greece
State/province [93] 0 0
Athens
Country [94] 0 0
Greece
State/province [94] 0 0
Chalkida
Country [95] 0 0
Greece
State/province [95] 0 0
N. Efkarpia, Thessaloniki
Country [96] 0 0
Greece
State/province [96] 0 0
Thessaloniki
Country [97] 0 0
Hong Kong
State/province [97] 0 0
Chai Wan
Country [98] 0 0
Hong Kong
State/province [98] 0 0
Kowloon
Country [99] 0 0
Hong Kong
State/province [99] 0 0
Shatin, New Territories
Country [100] 0 0
Hungary
State/province [100] 0 0
Balatonfüred
Country [101] 0 0
Hungary
State/province [101] 0 0
Budapest
Country [102] 0 0
Hungary
State/province [102] 0 0
Szolnok
Country [103] 0 0
Hungary
State/province [103] 0 0
Zalaegerszeg
Country [104] 0 0
Israel
State/province [104] 0 0
Ashkelon
Country [105] 0 0
Israel
State/province [105] 0 0
Haddera
Country [106] 0 0
Israel
State/province [106] 0 0
Kfar Saba
Country [107] 0 0
Israel
State/province [107] 0 0
Nahariya
Country [108] 0 0
Israel
State/province [108] 0 0
Tel Aviv
Country [109] 0 0
Italy
State/province [109] 0 0
Emilia-Romagna
Country [110] 0 0
Italy
State/province [110] 0 0
Friuli-Venezia-Giulia
Country [111] 0 0
Italy
State/province [111] 0 0
Lombardia
Country [112] 0 0
Italy
State/province [112] 0 0
Umbria
Country [113] 0 0
Korea, Republic of
State/province [113] 0 0
Daejeon
Country [114] 0 0
Korea, Republic of
State/province [114] 0 0
Ganwon-do
Country [115] 0 0
Korea, Republic of
State/province [115] 0 0
Gwangju
Country [116] 0 0
Korea, Republic of
State/province [116] 0 0
Seoul
Country [117] 0 0
Mexico
State/province [117] 0 0
Jalisco
Country [118] 0 0
Mexico
State/province [118] 0 0
Queretaro
Country [119] 0 0
Mexico
State/province [119] 0 0
San Luis Potosi
Country [120] 0 0
Netherlands
State/province [120] 0 0
Alkmaar
Country [121] 0 0
Netherlands
State/province [121] 0 0
Amersfoort
Country [122] 0 0
Netherlands
State/province [122] 0 0
Amsterdam
Country [123] 0 0
Netherlands
State/province [123] 0 0
Delft
Country [124] 0 0
Netherlands
State/province [124] 0 0
Deventer
Country [125] 0 0
Netherlands
State/province [125] 0 0
Helmond
Country [126] 0 0
Netherlands
State/province [126] 0 0
Nieuwegein
Country [127] 0 0
Netherlands
State/province [127] 0 0
Nijmegen
Country [128] 0 0
Netherlands
State/province [128] 0 0
Rotterdam
Country [129] 0 0
Netherlands
State/province [129] 0 0
Schiedam
Country [130] 0 0
Netherlands
State/province [130] 0 0
Sittard-geleen
Country [131] 0 0
Netherlands
State/province [131] 0 0
Tilburg
Country [132] 0 0
Netherlands
State/province [132] 0 0
Venlo
Country [133] 0 0
Netherlands
State/province [133] 0 0
Zwolle
Country [134] 0 0
New Zealand
State/province [134] 0 0
Christchurch
Country [135] 0 0
New Zealand
State/province [135] 0 0
Grafton, Auckland
Country [136] 0 0
New Zealand
State/province [136] 0 0
Hamilton
Country [137] 0 0
New Zealand
State/province [137] 0 0
New Plymouth
Country [138] 0 0
New Zealand
State/province [138] 0 0
Otahuhu, Auckland
Country [139] 0 0
New Zealand
State/province [139] 0 0
Wellington South
Country [140] 0 0
Norway
State/province [140] 0 0
Lillehammer
Country [141] 0 0
Norway
State/province [141] 0 0
Oslo
Country [142] 0 0
Norway
State/province [142] 0 0
Skien
Country [143] 0 0
Norway
State/province [143] 0 0
Stavanger
Country [144] 0 0
Norway
State/province [144] 0 0
Tromsø
Country [145] 0 0
Philippines
State/province [145] 0 0
Manila
Country [146] 0 0
Philippines
State/province [146] 0 0
Pasig City
Country [147] 0 0
Philippines
State/province [147] 0 0
Quezon City
Country [148] 0 0
Philippines
State/province [148] 0 0
San Juan
Country [149] 0 0
Poland
State/province [149] 0 0
Bydgoszcz
Country [150] 0 0
Poland
State/province [150] 0 0
Gdansk
Country [151] 0 0
Poland
State/province [151] 0 0
Gdynia
Country [152] 0 0
Poland
State/province [152] 0 0
Inowroclaw
Country [153] 0 0
Poland
State/province [153] 0 0
Krakow
Country [154] 0 0
Poland
State/province [154] 0 0
Lubin
Country [155] 0 0
Poland
State/province [155] 0 0
Lublin
Country [156] 0 0
Poland
State/province [156] 0 0
Olsztyn
Country [157] 0 0
Poland
State/province [157] 0 0
Torun
Country [158] 0 0
Poland
State/province [158] 0 0
Walbrzych
Country [159] 0 0
Poland
State/province [159] 0 0
Warszawa
Country [160] 0 0
Poland
State/province [160] 0 0
Wroclaw
Country [161] 0 0
Romania
State/province [161] 0 0
Bucharest
Country [162] 0 0
Romania
State/province [162] 0 0
Craiova
Country [163] 0 0
Russian Federation
State/province [163] 0 0
Barnaul
Country [164] 0 0
Russian Federation
State/province [164] 0 0
Gatchina
Country [165] 0 0
Russian Federation
State/province [165] 0 0
Irkutsk
Country [166] 0 0
Russian Federation
State/province [166] 0 0
Kemerovo
Country [167] 0 0
Russian Federation
State/province [167] 0 0
Moscow
Country [168] 0 0
Russian Federation
State/province [168] 0 0
Novosibirsk
Country [169] 0 0
Russian Federation
State/province [169] 0 0
Perm
Country [170] 0 0
Russian Federation
State/province [170] 0 0
Ryazan
Country [171] 0 0
Russian Federation
State/province [171] 0 0
Samara
Country [172] 0 0
Russian Federation
State/province [172] 0 0
Saratov
Country [173] 0 0
Russian Federation
State/province [173] 0 0
St-Petersburg
Country [174] 0 0
Russian Federation
State/province [174] 0 0
St. Petersburg
Country [175] 0 0
Russian Federation
State/province [175] 0 0
Tomsk
Country [176] 0 0
Russian Federation
State/province [176] 0 0
Tyumen
Country [177] 0 0
Slovakia
State/province [177] 0 0
Bratislava
Country [178] 0 0
Slovakia
State/province [178] 0 0
Kosice
Country [179] 0 0
Slovakia
State/province [179] 0 0
Martin
Country [180] 0 0
Slovakia
State/province [180] 0 0
Nitra
Country [181] 0 0
South Africa
State/province [181] 0 0
Bellville
Country [182] 0 0
South Africa
State/province [182] 0 0
Cape Town
Country [183] 0 0
South Africa
State/province [183] 0 0
Kuils River
Country [184] 0 0
South Africa
State/province [184] 0 0
Parktown West
Country [185] 0 0
South Africa
State/province [185] 0 0
Pinelands
Country [186] 0 0
South Africa
State/province [186] 0 0
Somerset West
Country [187] 0 0
Spain
State/province [187] 0 0
Barcelona
Country [188] 0 0
Spain
State/province [188] 0 0
Galdakano
Country [189] 0 0
Spain
State/province [189] 0 0
Madrid
Country [190] 0 0
Spain
State/province [190] 0 0
Majadahonda (Madrid)
Country [191] 0 0
Spain
State/province [191] 0 0
Malaga
Country [192] 0 0
Spain
State/province [192] 0 0
Marid
Country [193] 0 0
Spain
State/province [193] 0 0
Santiago De Compostela
Country [194] 0 0
Spain
State/province [194] 0 0
Sevilla
Country [195] 0 0
Sweden
State/province [195] 0 0
Göteborg
Country [196] 0 0
Sweden
State/province [196] 0 0
Helsingborg
Country [197] 0 0
Sweden
State/province [197] 0 0
Jönköping
Country [198] 0 0
Sweden
State/province [198] 0 0
Stockholm
Country [199] 0 0
Sweden
State/province [199] 0 0
Västerås
Country [200] 0 0
Sweden
State/province [200] 0 0
Örebro
Country [201] 0 0
Sweden
State/province [201] 0 0
Östersund
Country [202] 0 0
Taiwan
State/province [202] 0 0
Changhua
Country [203] 0 0
Taiwan
State/province [203] 0 0
Hualien
Country [204] 0 0
Taiwan
State/province [204] 0 0
Kaohsiung
Country [205] 0 0
Taiwan
State/province [205] 0 0
Taipei City
Country [206] 0 0
Taiwan
State/province [206] 0 0
Taipei
Country [207] 0 0
Thailand
State/province [207] 0 0
Bangkok
Country [208] 0 0
Thailand
State/province [208] 0 0
Chiangmai
Country [209] 0 0
Ukraine
State/province [209] 0 0
Cherkassy
Country [210] 0 0
Ukraine
State/province [210] 0 0
Ivano-Frankivsk
Country [211] 0 0
Ukraine
State/province [211] 0 0
Kharkiv
Country [212] 0 0
Ukraine
State/province [212] 0 0
Kyiv
Country [213] 0 0
Ukraine
State/province [213] 0 0
Lviv
Country [214] 0 0
Ukraine
State/province [214] 0 0
Uzhhorod
Country [215] 0 0
Ukraine
State/province [215] 0 0
Zaporizhzhya
Country [216] 0 0
United Kingdom
State/province [216] 0 0
Basingstoke
Country [217] 0 0
United Kingdom
State/province [217] 0 0
Bournemouth
Country [218] 0 0
United Kingdom
State/province [218] 0 0
Dundee
Country [219] 0 0
United Kingdom
State/province [219] 0 0
Edinburgh
Country [220] 0 0
United Kingdom
State/province [220] 0 0
Newcastle-upon-Tyne
Country [221] 0 0
United Kingdom
State/province [221] 0 0
York

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
GlaxoSmithKline
Address
Country
Other collaborator category [1] 0 0
Other
Name [1] 0 0
The TIMI Study Group
Address [1] 0 0
Country [1] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
Losmapimod is a new anti-inflammatory medication which potentially may benefit patients with Acute Coronary Syndrome, (ACS), a condition which includes heart attack. There is a growing understanding that the inflammatory response to ACS is integral to the subsequent evolution of plaque instability. Losmapimod inhibits p38 mitogen activated protein kinase (MAPK), an enzyme which may play a central role in inflammation in the setting of heart attack. Inhibition of p38 MAPK may stabilize atherosclerotic plaques, reduce the risk of subsequent plaque rupture, indirectly improve vascular function and prevent subsequent thrombosis, and thus reduce infarct size and the risk of subsequent cardiac events. This study will test whether losmapimod can safely reduce the risk of a subsequent cardiovascular event (such as death, heart attack, or near heart attack requiring urgent treatment ) when started immediately after ACS (specifically, heart attack). Patients who present with heart attack and qualify for the study will be randomly assigned to receive 3 months treatment with either losmapimod twice daily or placebo, which will be administered in addition to the usual standard of care therapies for heart attack. Following the in-hospital period, subjects will return for outpatient visits at 4 and 12 weeks, as well as a follow up visit at 24 weeks.
Trial website
https://clinicaltrials.gov/study/NCT02145468
Trial related presentations / publications
Cavender MA, O'Donoghue ML, Abbate A, Aylward P, Fox KA, Glaser RX, Park JG, Lopez-Sendon J, Steg PG, Sabatine MS, Morrow DA. Inhibition of p38 MAP kinase in patients with ST-elevation myocardial infarction - findings from the LATITUDE-TIMI 60 trial. Am Heart J. 2022 Jan;243:147-157. doi: 10.1016/j.ahj.2021.08.022. Epub 2021 Sep 8.
O'Donoghue ML, Glaser R, Cavender MA, Aylward PE, Bonaca MP, Budaj A, Davies RY, Dellborg M, Fox KA, Gutierrez JA, Hamm C, Kiss RG, Kovar F, Kuder JF, Im KA, Lepore JJ, Lopez-Sendon JL, Ophuis TO, Parkhomenko A, Shannon JB, Spinar J, Tanguay JF, Ruda M, Steg PG, Theroux P, Wiviott SD, Laws I, Sabatine MS, Morrow DA; LATITUDE-TIMI 60 Investigators. Effect of Losmapimod on Cardiovascular Outcomes in Patients Hospitalized With Acute Myocardial Infarction: A Randomized Clinical Trial. JAMA. 2016 Apr 19;315(15):1591-9. doi: 10.1001/jama.2016.3609.
O'Donoghue ML, Glaser R, Aylward PE, Cavender MA, Crisp A, Fox KA, Laws I, Lopez-Sendon JL, Steg PG, Theroux P, Sabatine MS, Morrow DA. Rationale and design of the LosmApimod To Inhibit p38 MAP kinase as a TherapeUtic target and moDify outcomes after an acute coronary syndromE trial. Am Heart J. 2015 May;169(5):622-630.e6. doi: 10.1016/j.ahj.2015.02.012. Epub 2015 Feb 23.
Public notes

Contacts
Principal investigator
Name 0 0
GSK Clinical Trials
Address 0 0
GlaxoSmithKline
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT02145468